BSE Live
Sep 18, 09:27Prev. Close
2042.00
Open Price
2030.75
Bid Price (Qty.)
2065.20 (9)
Offer Price (Qty.)
2067.80 (14)
NSE Live
Sep 18, 09:27Prev. Close
2042.40
Open Price
2049.90
Bid Price (Qty.)
2066.70 (335)
Offer Price (Qty.)
2066.90 (5)
Cash Flow of Glenmark Pharma (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
Net Profit/Loss Before Extraordinary Items And Tax | 2,154.02 | 7,000.75 | 1,571.87 | 2,337.45 | 1,943.76 | |
Net CashFlow From Operating Activities | 588.80 | -495.45 | 1,474.06 | 1,216.07 | 1,243.42 | |
Net Cash Used In Investing Activities | -489.52 | 3,197.19 | -431.47 | -896.92 | -1,235.23 | |
Net Cash Used From Financing Activities | -95.41 | -2,666.45 | -978.50 | -305.12 | -80.79 | |
Foreign Exchange Gains / Losses | -0.38 | -0.02 | -0.05 | -0.10 | 0.04 | |
Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
Net Inc/Dec In Cash And Cash Equivalents | 3.49 | 35.27 | 64.05 | 13.93 | -72.57 | |
Cash And Cash Equivalents Begin of Year | 127.96 | 92.70 | 28.65 | 14.72 | 87.29 | |
Cash And Cash Equivalents End Of Year | 131.45 | 127.96 | 92.70 | 28.65 | 14.72 |
27.05.2025
Glenmark Standalone March 2025 Net Sales at Rs 2,009.49 crore, down 6.46% Y-o-Y
04.03.2025
Glenmark Consolidated December 2024 Net Sales at Rs 3,387.55 crore, up 35.14% Y-o-Y
03.12.2024
Glenmark Consolidated September 2024 Net Sales at Rs 3,433.80 crore, up 7.06% Y-o-Y
20.11.2024
Glenmark Standalone September 2024 Net Sales at Rs 2,636.10 crore, up 18.03% Y-o-Y
08.07.2022
Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
14.04.2022
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
13.01.2022
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
06.10.2021
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
31.05.2019
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
09.02.2018
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
28.07.2017
31.07.2015